Indaptus Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $6,157,701 | $5,786,753 |
| Prepaid expenses and other current assets | 255,357 | 831,577 |
| Total current assets | 6,413,058 | 6,618,330 |
| Non-current assets: | ||
| Right-of-use asset | 33,577 | 82,175 |
| Other assets - deposits to third parties | 392,572 | 638,251 |
| Total non-current assets | 426,149 | 720,426 |
| Total assets | $6,839,207 | $7,338,756 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable and other current liabilities | $1,975,687 | $3,309,717 |
| Operating lease liability, current portion | 34,373 | 84,164 |
| Fair value of convertible promissory notes (Note 7) | 6,502,503 | - |
| Total current liabilities | 8,512,563 | 3,393,881 |
| Commitments and contingencies (Note 8) | - | - |
| Stockholders’ equity: | ||
| Common stock: $0.01 par value, 200,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 604,963 shares issued and outstanding as of June 30, 2025 and 428,799 shares issued and outstanding as of December 31, 2024* | 6,050 | 4,288 |
| Preferred stock: $0.01 par value, 5,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued or outstanding | - | - |
| Additional paid in capital* | 68,521,126 | 64,379,770 |
| Accumulated deficit | (70,200,532) | (60,439,183) |
| Total stockholders’ equity (deficit) | (1,673,356) | 3,944,875 |
| Total liabilities and stockholders’ equity (deficit) | $6,839,207 | $7,338,756 |
| * | Retroactively restated for one-for-twenty-eight share consolidation on June 27, 2025. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.